Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors
Authors:
Open Access
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 43 (6) , 1092-1111
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- Novartis Pharmaceuticals Corporation
This publication has 40 references indexed in Scilit:
- Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapyNature Reviews Cancer, 2018
- Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challengesNature Reviews Clinical Oncology, 2017
- Activity of crizotinib in relapsed MET amplified malignancies: Results of the French AcSé Program.Journal of Clinical Oncology, 2015
- MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressureCurrent Opinion in Cell Biology, 2014
- Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).Journal of Clinical Oncology, 2014
- MET As a Possible Target for Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingProceedings of the National Academy of Sciences, 2007
- Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Proceedings of the National Academy of Sciences, 2006
- c-Met as a target for human cancer and characterization of inhibitors for therapeutic interventionCancer Letters, 2005
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003